Search

Your search keyword '"Soong, David"' showing total 192 results

Search Constraints

Start Over You searched for: Author "Soong, David" Remove constraint Author: "Soong, David"
192 results on '"Soong, David"'

Search Results

1. Improving accuracy of GPT-3/4 results on biomedical data using a retrieval-augmented language model

4. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

7. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B‐cell lymphoma

8. Abstract 3248: Pharmacodynamic activity of epcoritamab (GEN3013; CD3xCD20) as monotherapy is maintained in combination with standard of care therapies in patients with diffuse large B-cell lymphoma

10. Transcriptomic Comparison of Non-Hodgkin Lymphomas in Relapsed/Refractory Versus Newly Diagnosed Patients Using Single FFPE Slides

11. Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

12. Deep Peripheral T Cell Immune-Profiling in Relapsed/Refractory Non-Hodgkin Lymphoma: Evaluation of Baseline Samples from the Epcoritamab Epcore NHL-1 Trial

13. 1299 Predicting CD8+ cell density and tumor-immune phenotypes in non-small-cell lung cancer (NSCLC) from standard H&E slides using deep learning (DL)

14. 987 Comprehensive immunophenotyping and genomics from single blood tube for T-cell dynamics in clinical trials

15. 1289 Predicting response to immune checkpoint inhibitors (ICI) in non-small-cell lung cancer (NSCLC) by combining spatial analysis of cells and RNA sequencing data from biopsies using deep learning (DL)

17. DLBCL cell of origin typing and whole transcriptome analysis using single slides with HTG EdgeSeq.

21. Additional file 2 of CNV Radar: an improved method for somatic copy number alteration characterization in oncology

22. Additional file 1 of CNV Radar: an improved method for somatic copy number alteration characterization in oncology

23. Additional file 3 of CNV Radar: an improved method for somatic copy number alteration characterization in oncology

24. Additional file 4 of CNV Radar: an improved method for somatic copy number alteration characterization in oncology

26. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression.

27. Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.

28. Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk.

29. Immunogenomic Exploration of the Acute Myeloid Leukemia Microenvironment Identifies Determinants of T-Cell Fitness

30. A Course in Polymer Processing.

31. A Course in Polymer Processing.

32. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

35. Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.

36. Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.

37. Depth of Response and MRD with Daratumumab Plus Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM: CASTOR

38. Daratumumab, Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM Based on Prior Lines and Treatment Exposure: POLLUX

39. Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM Based on Prior Lines and Treatment Exposure: CASTOR

40. A model for laser marking of thin organic data storage layers by short intense pulses.

41. Rheology of microsphere formation and refinement.

46. Abstract LB-248: Protein arginine methyltransferase 5 (PRMT5) inhibition as a therapeutic strategy in B-cell lymphoma

47. Abstract 2867: Inhibition of BET bromodomain proteins as a therapeutic approach in small cell lung cancer

48. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC

Catalog

Books, media, physical & digital resources